This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohkawara, T.
Right arrow Articles by Nishihira, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohkawara, T.
Right arrow Articles by Nishihira, J.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, October 2005, p. 1257-1258, Vol. 12, No. 10
1071-412X/05/$08.00+0     doi:10.1128/CDLI.12.10.1257-1258.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Increased Levels of Macrophage Migration Inhibitory Factor in Sera of Patients with Escherichia coli O157:H7-Induced Enterocolitis


arrow
LETTER
 
Verotoxin-producing Escherichia coli O157:H7 is a pathogen that causes severe hemorrhagic enterocolitis and sometimes leads to serious conditions such as hemolytic-uremic syndrome. Various inflammatory parameters have been assessed for their efficacy in predicting the severity of E. coli O157:H7-induced colitis (9, 10), but no serological biomarker has been identified which can precisely determine the presence and severity of this colitis. Macrophage migration inhibitory factor (MIF) is a unique cytokine that has been shown to play a role in several inflammatory diseases (4, 7). We here report increased levels of MIF in sera of patients with verotoxin-producing E. coli O157:H7-induced enterocolitis.

Serum samples were obtained from 24 patients with E. coli O157:H7-induced enterocolitis, 30 sex- and age-matched patients with bacterial enterocolitis induced by pathogens other than O157:H7 (Salmonella, Vibrio, and non-verotoxigenic E. coli) as disease controls, and 55 healthy individuals as normal controls. Serum MIF concentrations were measured with an enzyme-linked immunosorbent assay specific for MIF (IDLISA; Sapporo Immunodiagnostic Laboratory, Sapporo, Japan) as described previously (7). E. coli O157:H7 was diagnosed by stool culture, which is the gold standard diagnostic method for this pathogen.

As shown in Fig. 1, the serum MIF levels in patients with E. coli O157:H7-induced enterocolitis (23.67 ± 2.36 ng/ml; P < 0.001 versus normal controls and disease controls) were sixfold higher than those in normal controls and threefold higher than those in disease controls (3.99 ± 0.17 and 8.23 ± 0.60 ng/ml, respectively). Furthermore, serum MIF levels provided a level of differentiation of subjects with E. coli O157:H7-induced enterocolitis that was comparable to that afforded by detection of E. coli O157:H7 from stool culture (cutoff value, sensitivity, specificity, and positive predictive value by serum MIF: 12.5 ng/ml, 0.875, 0.950, and 0.840, respectively). On the other hand, leukocyte counts and levels of C-reactive protein in peripheral blood samples were increased in patients with E. coli O157:H7-induced enterocolitis and disease controls compared with normal controls, but there was no significant difference between patients with E. coli O157:H7-induced enterocolitis and disease controls (data not shown).



View larger version (10K):
[in this window]
[in a new window]
  		FIG. 1. Serum MIF concentrations in infectious colitis induced by verotoxin-producing E. coli O157:H7. Values are means ± standard error. Serum MIF levels were measured in 55 normal controls (NC), 30 patients with bacterial colitis induced by pathogens other than E. coli O157:H7 as disease controls (DC), and 24 patients with E. coli O157:H7-induced colitis (O157:H7). Subjects were matched for the time interval elapsed between the onset of enterocolitis and blood sample collection. Serum MIF concentrations were significantly higher in patients with E. coli O157:H7-induced enterocolitis than in normal controls and disease controls. *, P < 0.001. Results were statistically analyzed using the Mann-Whitney U test.

We previously demonstrated that MIF is a pivotal cytokine in the pathogenesis of inflammatory bowel disease and other types of colitis (8). In addition, recent studies have shown that MIF is immediately released in large quantities from the pituitary and other tissues in response to lipopolysaccharide (LPS) (1, 3). In particular, increased MIF levels in serum have been reported in patients with endotoxemias such as sepsis (4, 6). In mice, targeted disruption of MIF diminishes the immune response to LPS (2). Thus, MIF is considered to be an important molecule in the development of endotoxemia and subsequent severe inflammation.

It has been hypothesized that LPS is involved in the pathophysiology of verotoxigenic E. coli infection (5). In this study, we showed that serum MIF levels were markedly increased in patients with verotoxin-producing E. coli O157:H7-induced colitis compared with those in patients with nonspecific colitis and healthy individuals. These findings suggest that the acute-phase response of circulating MIF to the endotoxin induced by E. coli O157:H7 plays a role in the development of enterocolitis. Although further studies are needed to clarify the role of MIF in the pathophysiology of E. coli O157:H7-induced colitis, MIF may make a major contribution to the development of enterocolitis caused by verotoxigenic E. coli O157:H7.


arrow
REFERENCES
 
    1
  1. Bernhagen, J., T. Calandra, R. A. Mitchell, S. B. Martin, K. J. Tracey, W. Voelter, K. R. Manogue, A. Cerami, and R. Bucala. 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756-759.[CrossRef][Medline]
    2. 2
  2. Bozza, M., A. R. Satoskar, G. Lin, B. Lu, A. A. Humbles, C. Gerard, and J. R. David. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189:341-346.[Abstract/Free Full Text]
    3. 3
  3. Bucala, R. 1994. Identification of MIF as a new pituitary hormone and macrophage cytokine and its role in endotoxic shock. Immunol. Lett. 43:23-26.[Medline]
    4. 4
  4. Calandra, T., B. Echtenacher, D. L. Roy, J. Pugin, C. N. Metz, L. Hultner, D. Heumann, D. Mannel, R. Bucala, and M. P. Glauser. 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6:164-170.[CrossRef][Medline]
    5. 5
  5. Karpman, D., H. Connell, M. Svensson, F. Scheutz, P. Alm, and C. Svanborg. 1997. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J. Infect. Dis. 175:611-620.[Medline]
    6. 6
  6. Lehmann, L. E., U. Novender, S. Schroeder, T. Pietsch, T. V. Spiegel, C. Putensen, A. Hoeft, and F. Stuber. 2001. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med. 27:1412-1415.[CrossRef][Medline]
    7. 7
  7. Mizue, Y., J. Nishihira, T. Miyazaki, S. Fujiwara, M. Chida, K. Nakamura, K. Kikuchi, and M. Mukai. 2000. Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. Int. J. Mol. Med. 5:397-403.[Medline]
    8. 8
  8. Ohkawara, T., J. Nishihira, H. Takeda, S. Hige, M. Kato, T. Sugiyama, T. Iwanaga, H. Nakamura, Y. Mizue, and M. Asaka. 2002. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 123:256-270.[CrossRef][Medline]
    9. 9
  9. Proulx, F., C. Litalien, J. P. Turgeon, M. M. Mariscalco, and E. Seidman. 1998. Inflammatory mediators in hemorrhagic colitis and hemolytic uremic syndrome. Pediatr. Infect. Dis. J. 17:899-904.[CrossRef][Medline]
    10. 10
  10. Proux, F., E. Seidman, M. M. Mariscalco, K. Lee, and S. Caroll. 1999. Increased circulating levels of lipopolysaccharide binding protein in children with Escherichia coli O157:H7 hemorrhagic colitis and hemolytic uremic syndrome. Clin. Diagn. Lab. Immunol. 6:773. (Letter.)[Free Full Text]
Tatsuya Ohkawara*
Hiroshi Takeda
Masahiro Asaka
Department of Gastroenterology and Hematology
Hokkaido University Graduate School of Medicine
Sapporo, Japan,1

Yuka Mizue
Sapporo Immunodiagnostic Laboratory
Sapporo, Japan,2

Jun Nishihira
Department of Research and Development
GeneticLab
Sapporo, Japan,3

* Phone: 81 11 716 1161, Fax: 81 11 706 7867, E-mail: tokawara{at}med.hokudai.ac.jp

Clinical and Diagnostic Laboratory Immunology, October 2005, p. 1257-1258, Vol. 12, No. 10
1071-412X/05/$08.00+0     doi:10.1128/CDLI.12.10.1257-1258.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohkawara, T.
Right arrow Articles by Nishihira, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohkawara, T.
Right arrow Articles by Nishihira, J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»